Sarcoma News

Researchers from Japan recently confirmed that using carbon ion radiotherapy is effective in controlling cancer growth in patients with spinal sarcomas, according to a study published in Cancer.

Researchers from Japan recently confirmed that using carbon ion radiotherapy is effective in controlling cancer growth in patients with spinal sarcomas, according to a study published in Cancer.

Researchers in France have learned that the incidence of three AIDS-defining cancers — Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical cancer — has continued to decline, but the risk still remains higher than in the general population.

Researchers in France have learned that the incidence of three AIDS-defining cancers — Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical cancer — has continued to decline, but the risk still remains higher than in the general population.

The FDA and the European Medicines Agency have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony–stimulating factor-coding oncolytic adenovirus for the treatment of soft tissue sarcoma.

The FDA and the European Medicines Agency have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony–stimulating factor-coding oncolytic adenovirus for the treatment of soft tissue sarcoma.

Nearly half of the extremity soft tissue tumor surgeries in 85 medical centers studied during a 3-year period were performed by non-oncology-designated surgeons, such as general surgeons, plastic surgeons and orthopedic surgeons without post-medical fellowship training in cancer or sarcoma management, according to results of a study recently published in the Journal of Surgical Oncology.

Nearly half of the extremity soft tissue tumor surgeries in 85 medical centers studied during a 3-year period were performed by non-oncology-designated surgeons, such as general surgeons, plastic surgeons and orthopedic surgeons without post-medical fellowship training in cancer or sarcoma management, according to results of a study recently published in the Journal of Surgical Oncology.

The cost of the typical new cancer drug coming on the market in the United States has more than doubled in the past decade, from $4,500 per month of treatment to about $10,000 per month.

In this pilot study, the use of ligament advanced reinforcement system soft tissue reconstruction in combination with a megaprosthesis reconstruction provided good results for patients with osteosarcoma and chondrosarcoma.